TRIO Announces Participation in the Avoca Diligent(TM) Prequalification Platform
Diligent Leverages Avoca Quality Consortium(TM) Standards to Improve Quality and Reduce Cycle Time in the Prequalification of Technical Providers
EDMONTON, Alberta, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Translational Research in Oncology (TRIO) is pleased to announce its participation in the Avoca Diligent(TM) Prequalification Platform. The purpose of this initiative is to increase quality, improve efficiency, reduce risk, and accelerate technical service provider onboarding by centralizing aspects of prequalification activities.
Diligent was created by engaging an expert advisory board from the Avoca Quality Consortium to develop industry standards for prequalification of technical service providers. These standards were mapped, when possible, to health authority regulations or regulatory guidance. They underwent a rigorous review by The Avoca Group, the advisory board, and companies in the industry that deliver these technical services. Upon finalizing the prequalification industry standards, prequalification tools were developed that map back to these standards, including Request for Information (RFI) templates.
The Avoca Group has been inviting leading clinical service providers to submit completed RFIs and centralize them so they are readily available to sponsors (and clinical research organizations (CROs), if applicable) to expedite the process of prequalifying and onboarding new clinical service providers. TRIO has joined this transformational initiative and invites sponsors to contact The Avoca Group at Diligent@theavocagroup.com to request their completed RFI as needed to accelerate their review and onboarding of TRIO for their clinical trials.
"TRIO is excited to take part in the Diligent(TM) Prequalification Platform," shared Dr. Launa Aspeslet, TRIO's Chief Executive Officer. "TRIO is dedicated to bringing forward treatments which will benefit patients with cancer. TRIO is constantly looking at solutions to expedite trial conduct with the utmost quality. We expect this initiative to facilitate collaborations to run cancer clinical trials."
"The Avoca Group is pleased that TRIO has decided to participate in Diligent," says Patricia Leuchten, CEO of The Avoca Group. "This is another example of TRIO's commitment to advancing translational cancer research with novel and innovative approaches to delivering clinical trials efficiently and on time."
TRIO, together with its global network of dedicated investigators, is a not-for-profit academic oncology research organization offering full Clinical Research Organization (CRO) services to conduct its clinical trials. We are dedicated to advancing translational cancer research by bringing innovative and targeted therapeutics to clinical practice. Our mission is to further cancer research through our translational research model led by Dr. Dennis Slamon. TRIO conducts novel clinical trials with designs scientifically based on the preclinical findings from the Translational Oncology Research Laboratory (TORL) at UCLA. Additional information can be found by visiting www.trioncology.org.
About The Avoca Group
The Avoca Group, whose clients include top five pharmaceutical companies and global contract research organizations (CROs), is a driving force behind the continuous improvement of outsourced clinical research. In 2011, the Avoca Quality Consortium(TM), a pre-competitive collaborative, was formed and sponsored by Pfizer and Lilly. Members include more than 70 pharma, biotech, and clinical service providers. Founded in 1999, the company works exclusively in the health care industry with a focus on clinical research and clinical outsourcing. Learn more about The Avoca Group at www.theavocagroup.com and on LinkedIn and Twitter.
Launa Aspeslet, PhD, RAC
Matthieu Rupin, MSc
Business Development Director, TRIO
Email: email@example.com Phone: (+33) 1 58 10 08 89
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Translational Research in Oncology via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Comodo CA Sees 35 Percent Year-Over-Year Increase in EV Certificates22.3.2018 15:47 | Pressmeddelande
EV SSL will be a topic of discussion at the Comodo CA booth during RSA 2018 CLIFTON, N.J., March 22, 2018 (GLOBE NEWSWIRE) -- Comodo CA, a worldwide leader in digital identity solutions, will address evolving cyberthreats and the increasing importance Extended Validation (EV) TLS/SSL certificates play in securing websites and inspiring consumer trust at the RSA Conference 2018, San Francisco, April 16 - 20. According to the Feb 2018 Netcraft report, Comodo CA has seen a 35 percent year-over-year increase of EV certificate units* making it one of the fastest growing providers of high assurance certificates. The volume of EV certificates globally also saw a record year in 2017 as more and more businesses adopt EV as standard practice for their websites. The demand for stronger, more secure EV certificates comes in the wake of increased phishing websites using Domain Validated (DV) certificates. Phishing websites imitate legitimate websites to steal customers' funds and identities. Phishi
CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody22.3.2018 14:43 | Pressmeddelande
SAN DIEGO, March 22, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced today a strategic licensing agreement with CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies. The agreement gives CBT exclusive world-wide development and commercialization rights to a novel, recombinant, human monoclonal antibody which targets a differentiated epitope on the cytotoxic T-lymphocyte antigen-4 (CTLA-4) molecule. Binding of this antibody to CTLA-4 blocks the interaction of CTLA-4 with its ligands CD80/CD86 thus allowing the cytotoxic T cells to function actively. Under the terms of this global licensing agreement, CBT gain
Cloudflare Announces Mobile SDK to Monitor Network Performance for Applications22.3.2018 14:00 | Pressmeddelande
New free solution delivers network analytics to any mobile app developer SAN FRANCISCO, March 22, 2018 (GLOBE NEWSWIRE) -- Cloudflare, the leading Internet performance and security company, today announced the Cloudflare Mobile SDK, a free solution that enables any mobile app developer to understand network performance and metrics. Consumers are frustrated by mobile apps that are slow, crash, or deliver errors that degrade the user experience. For mobile app developers, a bad user experience means poor reviews, lower engagement, and reduced conversion on business metrics. Delivering consistent app performance requires focusing on every link in the chain: app code, network calls between the app and edge networks, and server infrastructure. There are a number of solutions that give developers analytics on their applications, but there has never been a way for app developers to understand how often their apps fail due to network errors. App developers easily integrate the Cloudflare Mobil
Compuware: Survey Shows Critical Mainframe Workloads Increasing While Mainframe Staff Losses Remain Unfilled22.3.2018 13:00 | Pressmeddelande
Many Organizations Not Measuring, Prioritizing Vital Key Performance Indicators 57 percent of enterprises with a mainframe currently run more than half of their business-critical applications on the platform-with that number expected to increase to 64 percent by next year. 72 percent of customer-facing applications are completely or very dependent on mainframe processing. Enterprises have only replaced 37 percent of the mainframe workforce lost over the past five years. Many organizations surveyed are not currently measuring velocity or efficiency key performance indicators, putting them at a disadvantage in the digital age. DETROIT, March 22, 2018 (GLOBE NEWSWIRE) -- The mainframe is becoming more important to large enterprises, with the percentage of organizations running at least half their business-critical applications on that platform expected to increase next year. However, the loss of skilled mainframe staff, and the failure to subsequently fill these positions, pose significan
Hoylu AB: HOYLU NAMED A 2018 TOP 25 COLLABORATION TECHNOLOGY COMPANY BY CIO APPLICATIONS22.3.2018 08:30 | Pressmeddelande
Malmo, Sweden, March 6, 2018 - Hoylu, a leading enterprise collaboration company today announced that CIO Applications Magazine has named Hoylu a Top 25 Collaboration Technology Company in 2018. CIO Applications presents each year the most innovative and unique companies, highlighting companies that excel in the space of Enterprise Collaboration Products and Technology. The Hoylu Product Suite allows users to collaborate quickly and easily with anyone around the world using a freeform or structured canvas and the ability to share workspaces in real time on any device. Hoylu was selected from many companies worldwide as a result of their unique approach to collaboration, which puts emphasis on the experience and putting the user first. The award recognizes Hoylu as a company at the forefront of providing innovative collaboration solutions to help companies and individuals work better and smarter together. "We are honored to be recognized among the leaders in the category of collaboratio
Hoylu AB: Hoylu ett topp 25 företag 2018 inom samarbete och teknologi utmärkelse från CIO Applications.22.3.2018 08:30 | Pressmeddelande
Malmö, 22 mars 2018 - Hoylu, ett ledande företag för samarbetslösningar, tillkännagav idag att CIO Applications Magazine har givit Hoylu utmärkelsen topp 25 inom samarbete och teknologi 2018. CIO Applications presenterar varje år de mest innovativa och unika företagen, och belyser företag som utmärker sig inom Enterprise Collaboration Products och teknologi. Hoylu Product Suite gör det möjligt för användare att samarbeta snabbt och enkelt med någon annan i en annan del av världen med hjälp av en friformad eller strukturerad duk och möjligheten att dela arbetsytor i realtid på vilken enhet som helst. Hoylu plockades ut från många företag över hela världen till följd av deras unika samarbetssätt, vilket lägger tonvikten på upplevelsen och användarupplevelsen Priset ger Hoylu ett erkännande för att vara ett företag som ligger i framkant och som erbjuder innovativa samarbetslösningar för att hjälpa företag och privatpersoner att arbeta bättre och smartare tillsammans. "Vi är hedrade att bl
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum